Consortium
The imSAVAR consortium was formed to provide a diversity of expertise on the ambition to deliver a sustainable platform of nonclinical tests that can more accurately reflect disease states.
28 partners from 11 countries provide expertise in the fields of: Immuno-safety, microphysiological systems, cellular in vitro assays as well as animal models, in vivo models, specific modes of action and adverse events, development of novel biomarkers, Management of samples and of a network of sampling providing centres, Data and knowledge management, bioinformatics solutions data privacy, innovation management, patient stakeholder involvement, sustainability planning and project management.
Academic
Universities, University Hospitals, a Federal Institute and Research Organisations from all over Europe are working together in imSAVAR.
EFPIA Companies
11 companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA) participate in imSAVAR, representing the pharmaceutical industry operating in Europe.
Associated Partners
We have one non-profit research organisation joining as an IMI associated partner.
SMEs
Within imSAVAR, we have 4 small-medium sized enterprises from Germany, Belgium and Luxembourg supporting the project.
Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is the world’s biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For the period 2014-2020 the IMI2 programme budget amounts to €3.3 billion.
IMI aims to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. This is done by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.
